Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer

IF 6.8 1区 医学 Q1 ONCOLOGY
Elisa De Paolis, Camilla Nero, Elisa Micarelli, Guido Leoni, Alessia Piermattei, Rita Trozzi, Elisa Scarselli, Anna Morena D’Alise, Luciano Giacò, Maria De Bonis, Alessia Preziosi, Gennaro Daniele, Diletta Piana, Tina Pasciuto, Gianfranco Zannoni, Angelo Minucci, Giovanni Scambia, Andrea Urbani, Francesco Fanfani
{"title":"Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer","authors":"Elisa De Paolis, Camilla Nero, Elisa Micarelli, Guido Leoni, Alessia Piermattei, Rita Trozzi, Elisa Scarselli, Anna Morena D’Alise, Luciano Giacò, Maria De Bonis, Alessia Preziosi, Gennaro Daniele, Diletta Piana, Tina Pasciuto, Gianfranco Zannoni, Angelo Minucci, Giovanni Scambia, Andrea Urbani, Francesco Fanfani","doi":"10.1038/s41698-024-00779-4","DOIUrl":null,"url":null,"abstract":"Endometrial cancer (EC) with Mismatch Repair deficiency (MMRd) is characterized by the accumulation of insertions/deletions at microsatellite sites. These mutations lead to the synthesis of frameshift peptides (FSPs) that represent tumor-specific neoantigens (nAg) proved to be shared across patients/tumors with MMRd. In this study, we explored the feasibility of a nAg-based cancer vaccination design in EC with MMRd. We adopted a whole exome sequencing approach and ad hoc bioinformatics pipelines to characterize FSPs in 35 patients with EC. A mean of 146 mutated mononucleotide repeats (MNRs) was identified with enrichment in the patients’ group with MLH1 impairment. A high coverage emerged from the comparative analysis of the EC FSPs with the content of the previously validated NOUS-209 vaccine. We obtained pieces of evidence of FSPs translation as expressed proteins from Ribo-seq, supporting the potential as the target of vaccination. The development of a nAgs-based vaccine strategy in MMRd EC may be further explored.","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":" ","pages":"1-9"},"PeriodicalIF":6.8000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41698-024-00779-4.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Precision Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41698-024-00779-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Endometrial cancer (EC) with Mismatch Repair deficiency (MMRd) is characterized by the accumulation of insertions/deletions at microsatellite sites. These mutations lead to the synthesis of frameshift peptides (FSPs) that represent tumor-specific neoantigens (nAg) proved to be shared across patients/tumors with MMRd. In this study, we explored the feasibility of a nAg-based cancer vaccination design in EC with MMRd. We adopted a whole exome sequencing approach and ad hoc bioinformatics pipelines to characterize FSPs in 35 patients with EC. A mean of 146 mutated mononucleotide repeats (MNRs) was identified with enrichment in the patients’ group with MLH1 impairment. A high coverage emerged from the comparative analysis of the EC FSPs with the content of the previously validated NOUS-209 vaccine. We obtained pieces of evidence of FSPs translation as expressed proteins from Ribo-seq, supporting the potential as the target of vaccination. The development of a nAgs-based vaccine strategy in MMRd EC may be further explored.

Abstract Image

错配修复缺陷子宫内膜癌中共享新抗原景观的特征。
错配修复缺陷(MMRd)的子宫内膜癌(EC)的特征是微卫星位点的插入/缺失积累。这些突变导致移码肽(FSPs)的合成,这些移码肽代表肿瘤特异性新抗原(nAg),被证明在MMRd患者/肿瘤中是共享的。在这项研究中,我们探讨了在伴有MMRd的EC中基于nag的癌症疫苗设计的可行性。我们采用全外显子组测序方法和特设生物信息学管道来表征35例EC患者的fsp。在MLH1损伤患者组中,平均鉴定出146个突变的单核苷酸重复序列(MNRs)富集。通过对EC fsp与先前验证的NOUS-209疫苗含量的比较分析,出现了高覆盖率。我们从Ribo-seq中获得了FSPs翻译为表达蛋白的证据,支持其作为疫苗接种靶点的潜力。在MMRd EC中开发基于nag的疫苗策略可以进一步探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.90
自引率
1.30%
发文量
87
审稿时长
18 weeks
期刊介绍: Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信